BTIG’s Sean Lavin believes it is “too early” for him to hike his sales expectations just yet for TRXC.
Transenterix Inc (NYSEAMERICAN:TRXC) announced its operating and financial results for the fourth quarter and full year 2017. Recent Highlights Thus far in the …
Tuesday turned out to be a nightmare for shareholders of drug maker Sarepta Therapeutics Inc (NASDAQ:SRPT) and surgical robot maker Transenterix Inc (NYSEMKT:TRXC), as the stock …
Transenterix Inc (NYSEMKT:TRXC) is down a whopping 65% in pre-market trading after the FDA determined that its SurgiBot system does not adequately meet …